Ksa Capital Management adds Relypsa Inc (RLYP) to its portfolio

Relypsa Inc (RLYP) : Ksa Capital Management added new position in Relypsa Inc during the most recent quarter end. The investment management firm now holds 5,000 shares of Relypsa Inc which is valued at $159,750 , the company said in a statement filed on Aug 15, 2016 with the SEC.Relypsa Inc makes up approximately 0.19% of Ksa Capital Management’s portfolio.

Other Hedge Funds, Including , Rock Springs Capital Management Lp added RLYP to its portfolio by purchasing 75,000 company shares during the most recent quarter which is valued at $2,396,250. Relypsa Inc makes up approx 0.17% of Rock Springs Capital Management Lp’s portfolio. Jefferies Group added RLYP to its portfolio by purchasing 100,000 company shares during the most recent quarter which is valued at $3,195,000. Relypsa Inc makes up approx 0.11% of Jefferies Group’s portfolio. Tower Research Capital (trc) added RLYP to its portfolio by purchasing 4,261 company shares during the most recent quarter which is valued at $136,139. Relypsa Inc makes up approx 0.01% of Tower Research Capital (trc)’s portfolio.Victory Capital Management Inc boosted its stake in RLYP in the latest quarter, The investment management firm added 330 additional shares and now holds a total of 727 shares of Relypsa Inc which is valued at $23,257.Rice Hall James Associates boosted its stake in RLYP in the latest quarter, The investment management firm added 1,676 additional shares and now holds a total of 132,850 shares of Relypsa Inc which is valued at $4,253,857. Relypsa Inc makes up approx 0.23% of Rice Hall James Associates’s portfolio.

On the company’s financial health, Relypsa Inc reported $-1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on May 4, 2016. Analyst had a consensus of $-1.44. The company had revenue of $12.40 million for the quarter, compared to analysts expectations of $7.10 million. During the same quarter in the previous year, the company posted $-0.78 EPS.

Many Wall Street Analysts have commented on Relypsa Inc. Relypsa Inc was Downgraded by Stifel to ” Hold” on Aug 22, 2016. Relypsa Inc was Downgraded by Cantor Fitzgerald to ” Hold” on Jul 26, 2016. Relypsa Inc was Downgraded by Guggenheim to ” Neutral” on Jul 26, 2016.

Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *